한글목차

전 세계 체외 폐 모델 시장은 2025년에 3억 3,800만 달러로 추정되며 2032년까지 8억 6,660만 달러에 달할 것으로 예상되며, 2025년부터 2032년까지 CAGR 14.4%로 성장할 것으로 예상됩니다.

그림. 체외 폐 모델 세계 시장 점유율(%), 지역별, 2025년

체외 폐 모델은 인간 폐의 생리적, 해부학적 특성을 모방하기 위한 실험 시스템입니다. 신약개발, 독성 시험, 폐질환 연구에 널리 이용되고 있습니다. 체외에서 배양한 인간 폐 세포 및 조직을 이용함으로써, 이들 모델은 동물 실험에 비해 상대적으로 저렴하고 효과적인 대안을 제공합니다. 또한 동물 모델과 비교하여 보다 현실적이고 제어 가능한 환경을 제공하여 인간 폐의 생물학 및 질병 병태를 연구할 수 있습니다. 향후 조직공학, 미세유체공학 및 기타 기술의 발전으로 생체 내 폐 미세 환경을 더 잘 재현할 수 있는 고도로 복잡한 3D 폐 모델 개발에 도움이 될 것으로 기대됩니다.

시장 역학:

세계 체외 폐 모델 시장은 제약회사의 의약품 연구개발 투자 증가, 동물실험에 대한 엄격한 규제, 호흡기질환의 유병률 증가 등의 요인에 의해 주도되고 있습니다. 그러나 첨단 3D 폐 모델 개발에 따른 높은 비용과 짧은 조직 보존 기간이 시장 성장을 억제할 것으로 예상됩니다. 반면, 미세 가공 기술 및 3D 바이오프린팅 기술의 발전으로 차세대 생체 모방 모델 개발에 큰 기회가 창출될 것으로 예상됩니다. 또한, 개별 환자 유래의 세포 및 조직이 포함된 맞춤형 폐 모델 개발이 주목받고 있어 시장 확대가 예상됩니다.

한편, 시장 진입 기업들의 연구개발이 증가함에 따라 예측 기간 동안 시장 성장을 더욱 촉진할 것으로 예상됩니다. 예를 들어, 2024년 3월 6일 생명공학 기업 AlveoliX AG는 Frontiers Media S.A.에 천식, 만성폐쇄성폐질환(COPD), 섬유증과 같은 다양한 호흡기질환에 대해 미국 식품의약국(FDA)이 개발한 약물의 수가 제한적이기 때문에 A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip"이라는 제목의 연구를 발표하였습니다. 이러한 심각한 폐 질환에 대해 미국 식품의약국(FDA)이 승인한 흡입 약물의 수가 제한적이기 때문에 전임상 연구에서 흡입 입자의 독성을 보다 정확하게 예측하기 위해 생체 내에서 대체할 수 있는 생체 외 인체 관련 모델 사용으로 전환하고 있습니다.

이 조사의 주요 특징

• 세계의 시험관내 폐 모델 시장을 상세히 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
• 또한, 다양한 부문에 걸친 잠재적 수익 기회를 파악하고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 체외 폐 모델 시장의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 체외 폐 모델 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 체외 폐 모델 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 가정

• 조사 목적
• 가정
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 서비스 제공 포트폴리오
• PEST 분석
• PORTER의 분석
• 인수합병 시나리오

제4장 세계의 체외 폐 모델 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측 분석
• 경제에 대한 영향

제5장 세계의 체외 폐 모델 시장, 유형별, 2020-2032년

• 2D 모델
• 3D 모델

제6장 세계의 체외 폐 모델 시장, 용도별, 2020-2032년

• Drug Discovery와 독성학 연구
• 생리학적 조사
• 3D 모델 개발
• 기타

제7장 세계의 체외 폐 모델 시장, 최종사용자별, 2020-2032년

• 학술조사기관
• 바이오의약품 기업
• 기타

제8장 세계의 체외 폐 모델 시장, 지역별, 2020-2032년

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제9장 경쟁 구도

• Epithelix
• MATTEK
• Lonza
• Emulate
• AlveoliX AG
• Nortis
• CN Bio Innovations Ltd
• MIMETAS
• InSphero
• ATTC Global
• Tissuse GmbH
• Cn Bio Innovations Limited

제10장 섹션

• 조사 방법
• 출판사 소개

영문목차

Global In Vitro Lung Model Market is estimated to be valued at USD 338.0 Mn in 2025 and is expected to reach USD 866.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 14.4% from 2025 to 2032.

Figure. Global In Vitro Lung Model Market Share (%), By Region 2025

In vitro lung models are experimental systems that aim to mimic the physiological and anatomical properties of the human lungs. They are widely used in drug discovery, toxicity testing, and studying lung diseases. By utilizing human lung cells and tissues grown outside of the body, these models offer a relatively affordable and effective alternative to animal testing. They also provide a more realistic and controllable environment to study human lung biology and disease pathology compared to animal models. Going forward, advances in tissue engineering, microfluidics, and other technologies are expected to help develop highly complex 3D lung models that can better recreate the in vivo lung microenvironment.

Market Dynamics:

The global in vitro lung model market is driven by factors such as rising drug R&D investments by pharmaceutical companies, stringent regulations regarding animal testing, and increasing prevalence of respiratory diseases. However, high costs associated with developing advanced 3D lung models and shorter shelf life of tissues are expected to restrain the market growth. Meanwhile, ongoing advances in microfabrication and 3D bioprinting technologies are projected to create significant opportunities for manufacturers to develop next-gen biomimetic models. The market is also anticipated to gain from growing focus on developing personalized lung models incorporating individual patient-derived cells and tissues.

On the other hand, rising research and development by market players is further expected to propel the market growth over the forecast period. For instance, on March 6, 2024, AlveoliX AG, a biotechnology company, published a study in Frontiers Media S.A., a peer-reviewed, open access, scientific journals, entitled "A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip" for various respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and fibrosis, due to limited number of U.S. Food and Drug Administration, approved inhaled drugs for these serious lung conditions has led to a shift from in vivo towards the use of alternative in vitro human-relevant models to better predict the toxicity of inhaled particles in preclinical research.

Key features of the study:

• This report provides an in-depth analysis of the global In vitro lung model market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global In vitro lung model market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Histogen Inc., OliX Pharmaceuticals, Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy's Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global In vitro lung model market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global In vitro lung model market

Detailed Segmentation:

• Global In Vitro Lung Model Market, By Type
  • 2D Model
  • 3D Model
• Global In Vitro Lung Model Market, By Application
  • Drug Discovery & Toxicology Studies
  • Physiological Research
  • 3D Model Development
  • Others
• Global In Vitro Lung Model Market, By End User
  • Academic and Research Institutes
  • Biopharmaceutical Companies
  • Others
• Global In Vitro Lung Model Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles
  • Histogen Inc.
  • OliX Pharmaceuticals
  • Cipla Limited
  • Aclaris Therapeutics, Inc.
  • Merck & Co., Inc.
  • Daiichi-Sankyo Co., Ltd.
  • Johnson and Johnson Services, Inc.
  • Lexington International LLC
  • Vita-Cos-Med Klett-Loch GmbH
  • PureTech
  • Vitabiotics
  • Dr. Reddy's Laboratories
  • HCell Inc.
  • Follica, Inc.
  • Ranbaxy Laboratories Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global In Vitro Lung Model Market, By Type
  • Global In Vitro Lung Model Market, By Application
  • Global In Vitro Lung Model Market, By End User
  • Global In Vitro Lung Model Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rising prevalence of lung diseases
  • High costs associated with animal models
  • Growing preference for 3D lung models over 2D models
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Service offering Portfolio
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global In Vitro Lung Model Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global In Vitro Lung Model Market, By Type, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• 2D Model
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• 3D Model
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global In Vitro Lung Model Market, By Application, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Drug Discovery & Toxicology Studies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Physiological Research
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• 3D Model Development
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global In Vitro Lung Model Market, By End User, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Academic and Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Biopharmaceutical Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global In Vitro Lung Model Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Epithelix
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• MATTEK
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lonza
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Emulate
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AlveoliX AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Nortis
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Strategies
• CN Bio Innovations Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• MIMETAS
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• InSphero
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• ATTC Global
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Tissuse GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Cn Bio Innovations Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us